arrow
T

Theodoros Tsakiridis

mcmaster university
H指数:38
被引数:6,832

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Canagliflozin Is a Novel Androgen Receptor Pathway Inhibitor for Castrate-Sensitive and Castrate-Resistant Prostate Cancer

卡格列净是一种新型雄激素受体通路抑制剂,用于去势敏感和去势抵抗性前列腺癌

2026-04-240
PRE
HER2-Specific Synthetic Antigen Receptor (SAR) T Cell Therapy Synergizes with Radiotherapy to Provide Improved Anti-Tumor Efficacy in Non-Small Cell Lung Cancer (NSCLC)

HER2特异性合成抗原受体(SAR)T细胞疗法与放疗协同作用,以提高非小细胞肺癌(NSCLC)的抗肿瘤效果。

2026-03-030
PRE
Geographical and Sociodemographic Disparities in Access to Radiotherapy in Brazil: A Nationwide Cross-Sectional Study (2017–2022)

巴西放射治疗可及性的地理和社会人口差异:一项全国性横断面研究(2017–2022)

2026-02-140
PRE
Dual inhibition of ACLY and ACSS2 by EVT0185 reduces steatosis, hepatic stellate cell activation, and fibrosis in mouse models of MASH

EVT0185对ACLY和ACSS2的双重抑制可减轻小鼠MASH模型中的脂肪变性、肝星状细胞激活和纤维化。

2026-01-060
OAAI
Quality of Life of Stereotactic vs. Hypofractionated Radiotherapy for Inoperable Stage I Non-Small Cell Lung Cancer: Results from the XXXXXX trial

立体定向放疗与低分割放疗治疗不可手术的Ⅰ期非小细胞肺癌的生活质量比较:XXXXXX试验的结果

2025-11-210
OAAI
Metastases-directed therapy in addition to standard systemic therapy in oligometastatic castration-resistant prostate cancer in Canada (GROUQ-PCS 9): a multicentre, open-label, randomised, phase 2 trial

在加拿大对寡转移性去势抵抗性前列腺癌进行转移灶导向治疗联合标准系统性治疗(GROUQ-PCS 9):一项多中心、开放标签、随机、Ⅱ期临床试验

2025-09-010
PRE
ACLY inhibition promotes tumour immunity and suppresses liver cancer

ACLY抑制促进肿瘤免疫和抑制肝癌

Nature
IF48.5
2025-07-300
OA
In Reply to Onal et al. Primary Analysis of (NCT03380806) a Phase II Randomized Trial of Stereotactic Body Radiotherapy Boost Versus Conventional Fractionation External Beam Radiotherapy Boost in Unfavorable-Intermediate and High-Risk Prostate Cancer

回复 Onal 等人:NCT03380806 的初步分析——一项关于立体定向体部放射治疗推量与常规分割外照射推量在不良预后中危和高危前列腺癌中的 II 期随机试验

2025-07-280
PRE
Patient-reported Quality of Life in PROFIT, a Phase 3 Randomized Clinical Trial Evaluating Moderately Hypofractionated Radiotherapy for Intermediate-risk Prostate Cancer

Pro益中患者报告的生活质量,一项3期随机临床试验,评估中度大分割放疗治疗中危前列腺癌

2025-05-060
PRE
Primary Analysis of (NCT03380806) a Phase II Randomized Trial of Stereotactic Body Radiotherapy Boost Versus Conventional Fractionation External Beam Radiotherapy Boost in Unfavorable-Intermediate and High-Risk Prostate Cancer

(NCT03380806)一项关于立体定向体部放射治疗加量与常规分割外照射放射治疗加量在不良-中危和高危前列腺癌中的随机Ⅱ期试验的初步分析

2025-04-271
OAAI
Growth differentiation factor 15 (GDF15) predicts relapse free and overall survival in unresected locally advanced non-small cell lung cancer treated with chemoradiotherapy

生长分化因子15 (GDF15) 预测未切除局部晚期非小细胞肺癌放化疗的无复发生存率和总生存率

2024-11-071
OAAI
The SGLT2 inhibitor canagliflozin suppresses growth and enhances prostate cancer response to radiotherapy

SGLT2抑制剂canagliflozin抑制生长并增强前列腺癌对放疗的反应

2023-09-0819
OAAI
Combination of an ACLY inhibitor with a GLP-1R agonist exerts additive benefits on nonalcoholic steatohepatitis and hepatic fibrosis in mice
2023-09-018
OAAI
Canagliflozin mediates tumor suppression alone and in combination with radiotherapy in non-small cell lung cancer (NSCLC) through inhibition of HIF-1a

Canagliflozin单独或联合放疗通过抑制HIF-1a介导非小细胞肺癌 (NSCLC) 的肿瘤抑制

2023-08-2712
OA
Metformin-induced reductions in tumor growth involves modulation of the gut microbiome
2022-07-0135
OAAI